Faron Pharmaceuticals Oy (AIM:FARN)
London · Delayed Price · Currency is GBP · Price in GBX 55.00
-2.50 (-4.35%)
Feb 12, 2026, 4:35 PM GMT
Faron Pharmaceuticals Oy Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
66.58M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| hVIVO | 54.47M |
| Bioventix | 13.12M |
| Arecor Therapeutics | 5.06M |
| Scancell Holdings | 4.71M |
| SkinBioTherapeutics | 4.64M |
| 4basebio | 1.78M |
| Aptamer Group | 1.20M |
| Ondine Biomedical | 1.18M |
Faron Pharmaceuticals Oy News
- 1 day ago - Faron Pharmaceuticals Oy (FPHAF) Discusses Clinical Progress and Development Plans for BEXMAB in High-Risk MDS Transcript - Seeking Alpha
- 7 months ago - Faron Pharmaceuticals To Earn Spotlight At IUIS 2025 With Its Bexmarilimab Data - IBTimes